Comment
Author: Admin | 2025-04-28
ModificationCholinergic Agonists: Beta-Blockers may enhance the adverse/toxic effect of Cholinergic Agonists. Of particular concern are the potential for cardiac conduction abnormalities and bronchoconstriction. Monitor therapyCloBAZam: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Monitor therapyCloZAPine: CYP1A2 Inhibitors (Weak) may increase the serum concentration of CloZAPine. Management: Drugs listed as exceptions to this monograph are discussed in further detail in separate drug interaction monographs. Monitor therapyCobicistat: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Monitor therapyCYP1A2 Inducers (Moderate): May decrease the serum concentration of Propranolol. Monitor therapyCYP1A2 Inhibitors (Moderate): May increase the serum concentration of Propranolol. Monitor therapyCYP1A2 Inhibitors (Strong): May increase the serum concentration of Propranolol. Management: Use a lower initial propranolol dose and be more cautious during propranolol dose titration when combined with strong CYP1A2 inhibitors. Consider therapy modificationCYP2D6 Inhibitors (Moderate): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). Monitor therapyCYP2D6 Inhibitors (Strong): May decrease the metabolism of CYP2D6 Substrates (High risk with Inhibitors). Consider therapy modificationDacomitinib: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Management: Avoid concurrent use of dacomitinib with CYP2D6 subtrates that have a narrow therapeutic index. Consider therapy modificationDarunavir: May increase the serum concentration of CYP2D6 Substrates (High risk with Inhibitors). Monitor therapyDexmethylphenidate: May diminish the therapeutic effect of Antihypertensive Agents. Monitor therapyDiazoxide: May enhance the hypotensive effect of Blood Pressure Lowering Agents. Monitor therapyDipyridamole: May enhance the bradycardic effect of Beta-Blockers. Monitor therapyDisopyramide: May enhance the bradycardic effect of Beta-Blockers. Beta-Blockers may enhance the negative inotropic effect of Disopyramide. Monitor therapyDoxofylline: Propranolol may increase the serum concentration of Doxofylline. Monitor therapyDronedarone: May enhance the bradycardic effect of Beta-Blockers. Dronedarone may increase the serum concentration of Beta-Blockers. This likely applies only to those agents that are metabolized by CYP2D6. Management: Use lower initial beta-blocker doses; adequate tolerance of the combination, based on ECG findings, should be confirmed prior to any increase in beta-blocker dose. Consider therapy modificationDULoxetine: Blood Pressure Lowering Agents may enhance the hypotensive effect of DULoxetine. Monitor therapyEPINEPHrine (Nasal): Beta-Blockers (Nonselective) may enhance the hypertensive effect of EPINEPHrine
Add Comment